Board of Directors
Johannes Fruehauf (Cambridge Biolabs), Peter Parker (BioInnovation LLC), and Tim Rowe (Cambridge Innovation Center) have created LabCentral based on their own experiences as entrepreuneurs and that of countless others who have spent precious time and resources searching for and equipping appropriate startup lab space. Clearly, there is a glaring need for such a facility centered in and around Cambridge and Boston designed specifically for the life-sciences community.
Chairman, Director, Co-Founder
CEO, Cambridge Innovation Center; Venture Partner, New Atlantic Ventures
Tim Rowe is the Founder and CEO of Cambridge Innovation Center. CIC is a recognized global leader that creates concentrated hubs of collaborative innovation in leading cities around the world. More than US $3.3B of venture capital has been invested in companies that grew up at CIC and its affiliates. Many success stories have come out of CIC, including that of Google Android co-Founder Rich Miner, who famously built his portion of that company at CIC. Approximately $7.2B of venture capital is headquartered in CIC’s Cambridge buildings alone, putting them on par with many countries.
In addition to its original Cambridge, MA location, CIC operates today in Boston, MA; St Louis, MO; Miami, FL; Rotterdam, the Netherlands. In January 2017, CIC announced its newest site: Philadelphia. Tim has served as a Lecturer at the MIT Sloan School of Management, a Manager with the Boston Consulting Group and an analyst with the Mitsubishi Research Institute. Tim speaks Spanish and Japanese fluently, and holds an MBA from MIT’s Sloan School of Management and a BA from Amherst College.
Johannes Fruehauf, MD, PhD
CEO, Cambridge Biolabs and ViThera Pharma; Cofounder, Cequent Pharmaceuticals
Johannes Fruehauf is a founder and the president and executive director of LabCentral. He is responsible for all aspects of LabCentral’s operation. Johannes is a physician and successful biotech entrepreneur. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. He is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. Johannes earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).
Managing General Partner, BioInnovation Capital; General Partner, Ampersand Ventures; Founding CEO, Boston Heart Dx; CEO, Cequent Pharma
Peter Parker is a founder and director of LabCentral. He chairs the selection committee and overseas board activities. He also conducts seed and early-stage life-sciences investing activities through BioInnovation Capital based in Cambridge, Mass. For the past several years, Peter has played a major role in the greater Boston/Cambridge healthcare start-up community. At MassChallenge, he was the healthcare/life sciences ‘Champion’ for five years. He is also a co-founder of BioLabs and several other local firms including Boston Heart Diagnostics, Deltix, and 5G Bio. LabCentral was born out of Peter’s and Johannes’ difficult search for lab space when they formed Cequent Pharmaceuticals together in 2006. For nearly 20 years, Peter was a general partner at Ampersand Capital Partners, Wellesley, Mass. He has been a board member and investor in more than 25 life sciences companies.
CEO, MassChallenge; Bain & Company
John Harthorne is the founder and CEO of MassChallenge, a startup accelerator and competition designed to catalyze a startup renaissance by connecting high-impact startups from around the world with the resources they need to launch and succeed. John received his MBA from the MIT Sloan School of Management in 2007. While at school, John received Grand Prize in the 2007 MIT $100K Business Plan Competition and received the 2007 Patrick J. McGovern Award for impact on quality and visibility of entrepreneurship at MIT. He also led the 10th annual MIT Global Startup Workshop (GSW) held in Trondheim, Norway. In September 2011, the Boston Business Journal identified John as one of “Boston’s 50 Most Influential Business Leaders.”
CEO, Forma Therapeutics; Novartis Venture Fund; Novartis Strategic Alliances
Steve Tregay is the founder, president and CEO of FORMA Therapeutics, a company building a robust pipeline of transformative cancer therapeutics directed in areas such as tumor metabolism, epigenetics and protein-protein interactions. Prior to joining FORMA, Steven Tregay was a managing director for the $200 million Novartis Option Fund. He led the fund’s investments in and served on the board of directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the executive director and head of strategic alliances – Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his doctoral and master’s degrees in organic chemistry from Harvard University and a bachelor’s from Davidson College.